scholarly journals Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma

Oncotarget ◽  
2017 ◽  
Vol 8 (27) ◽  
pp. 44418-44433 ◽  
Author(s):  
Axel Lechner ◽  
Hans Schlößer ◽  
Sacha I. Rothschild ◽  
Martin Thelen ◽  
Sabrina Reuter ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
T Lymphocyte ◽  
Squamous Cell ◽  
Immune Checkpoint ◽  
Lymphocyte Subsets ◽  
Neck Squamous Cell Carcinoma ◽  
T Lymphocyte Subsets

Decreased Absolute Counts of T Lymphocyte Subsets and Their Relation to Disease in Squamous Cell Carcinoma of the Head and Neck

2004 ◽  
Vol 10 (11) ◽  
pp. 3755-3762 ◽  
Author(s):  
Iris Kuss ◽  
Bridget Hathaway ◽  
Robert L. Ferris ◽  
William Gooding ◽  
Theresa L. Whiteside
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
T Lymphocyte ◽  
Squamous Cell ◽  
Lymphocyte Subsets ◽  
T Lymphocyte Subsets

T-Lymphocyte Subsets in Patients with Squamous Cell Carcinoma of the Head and Neck

1986 ◽  
Vol 13 ◽  
pp. S143-S148 ◽  
Author(s):  
Tohru Furusaka ◽  
Yutaka Yokode ◽  
Misako Nakajima ◽  
Hidenobu Iida ◽  
Akinori Kida ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
T Lymphocyte ◽  
Squamous Cell ◽  
Lymphocyte Subsets ◽  
T Lymphocyte Subsets

scholarly journals Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Medicina ◽  
2021 ◽  
Vol 57 (11) ◽  
pp. 1151
Author(s):  
Shinsuke Suzuki ◽  
Satoshi Toyoma ◽  
Yohei Kawasaki ◽  
Koh Koizumi ◽  
Nobuko Iikawa ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Neck Squamous Cell Carcinoma ◽  
Grade 3

Background and Objectives: In recent years, the effectiveness of chemotherapy after immune checkpoint inhibitor administration has attracted attention in various cancers, including head and neck cancers. However, individual assessments of the administered chemotherapy regimens are insufficient. This study aimed to evaluate the efficacy and safety of chemotherapy after immune checkpoint inhibitor administration in recurrent metastatic head and neck cancer by focusing on a single regimen. Materials and Methods: We retrospectively reviewed clinical and radiological data from the medical records of 18 patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who received systemic chemotherapy with weekly cetuximab and paclitaxel (Cmab + PTX) after progression following immune checkpoint inhibitor (ICI) therapy. The objective response rate (ORR) and disease control rate (DCR) were assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Adverse events (AEs) were recorded using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Results: In all patients, the ORR, DCR, median PFS, and median OS were 44.4%, 72.2%, 3.8 months, and 9.6 months, respectively. Regarding AEs, three patients developed grade 3 neutropenia. Grade 3 anemia, paronychia, asthenia, and peripheral neuropathy were observed in one patient each. There were no treatment-related deaths. Conclusions: Cmab + PTX was shown to maintain high efficacy and acceptable safety for R/M HNSCC that progressed after ICI therapy. Further research is needed to establish optimal treatment sequences and drug combinations for recurrent R/M HNSCC.

Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma

2003 ◽  
Vol 103 (6) ◽  
pp. 768-774 ◽  
Author(s):  
Arnolda G. de Nooij-van Dalen ◽  
Guus A.M.S. van Dongen ◽  
Serge J. Smeets ◽  
Eline J.C. Nieuwenhuis ◽  
Marijke Stigter-van Walsum ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Molecular Markers ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document